Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
Reply schreef op 17 januari 2020 11:05 :
[...]
Het zal daarbij vanzelfsprekend allemaal stapsgewijs gaan waarbij, zoals door meerderen hier op het forum aangegeven, de nadruk vooral zal liggen op de ontwikkelingen in de tweede jaarhelft van 2020.
De hatelijke € 5 regionen lijken nu in elk geval tot het verleden te behoren.
Forza Biocartis! ;-)
Volgens mij wordt Japan de grote groeimotor voor Bcart dit jaar. Ik denk dus niet dat we tot H2 moeten wachten om positief verrast te worden. De eerste tekenen van deze Japanse groei zullen we mogelijk reeds kunnen waarnemen op 5 maart bij de bekendmaking van de guidance voor 2020. Als mijn redenering in mijn post van 16 jan 2020 om 18:44 klopt, dan kunnen we dit jaar, zelfs als slechts 200 van de 2000 Japanse klanten van Nichirei besluiten een Idylla aan te schaffen, een zeer mooie groei tegemoet zien. Bcart verstrekt ons helaas onvoldoende concrete cijfers om aan mijn inschatting een grotere zekerheid te koppelen. BL
DRTVR schreef op 17 januari 2020 20:03 :
Ben maar een leek, dus als ik het goed begrijp, als men NGS toepast heeft men Idylla niet meer nodig?
Als men tussen de 100.000 en het miljoen Euro voor de aanschaf van zo'n toestel over heeft en een heel leger analisten om de data te interpreteren. BL
Das natuurlijk een ander gegeven, bedankt voor de reactie.
DRTVR schreef op 17 januari 2020 20:03 :
Ben maar een leek, dus als ik het goed begrijp, als men NGS toepast heeft men Idylla niet meer nodig?
Nee, zeker niet. Idylla is een op qPCR gebaseerd systeem. NGS is een andere methodiek voor medical diagnostics. Op pagina 7 van de bedrijfspresentatie zie je welke systemen er bestaan (NGS, PCR, Sanger sequencing, ea.).investors.biocartis.com/en/corporate-...
brightlight schreef op 17 januari 2020 20:10 :
[...]
Volgens mij wordt Japan de grote groeimotor voor Bcart dit jaar. Ik denk dus niet dat we tot H2 moeten wachten om positief verrast te worden. De eerste tekenen van deze Japanse groei zullen we mogelijk reeds kunnen waarnemen op 5 maart bij de bekendmaking van de guidance voor 2020. Als mijn redenering in mijn post van 16 jan 2020 om 18:44 klopt, dan kunnen we dit jaar, zelfs als slechts 200 van de 2000 Japanse klanten van Nichirei besluiten een Idylla aan te schaffen, een zeer mooie groei tegemoet zien. Bcart verstrekt ons helaas onvoldoende concrete cijfers om aan mijn inschatting een grotere zekerheid te koppelen.
BL
Op 5 maart met de officiële jaarcijfers 2019 verwacht ik zelf eerlijk gezegd minder spektakel, maar laat mijzelf natuurlijk ook graag positief verrassen ;-) Waarom dan minder spektakel? Feitelijk zijn de cijfers met de update van 9 Januari ondertussen bekend en zullen de uiteindelijke, door de accountant gecontroleerde, cijfers dan ook slechts marginaal verschillen. En wat betreft de guidance voor 2020 heeft Biocartis natuurlijk een harde les geleerd in 2019 en zal nu naar mijn verwachting eerder relatief voorzichtig zijn in hun guidance voor 2020. Beter en veiliger is het dan om mogelijk van kwartaal op kwartaal positief te gaan verrassen in 2020. Met het recente jaar 2019 in gedachten zou ik hen deze strategie ook geheel niet kwalijk nemen.
Reply schreef op 17 januari 2020 20:31 :
[...]
Op 5 maart met de officiële jaarcijfers 2019 verwacht ik zelf eerlijk gezegd minder spektakel, maar laat mijzelf natuurlijk ook graag positief verrassen ;-)
Waarom dan minder spektakel? Feitelijk zijn de cijfers met de update van 9 Januari ondertussen bekend en zullen de uiteindelijke, door de accountant gecontroleerde, cijfers dan ook slechts marginaal verschillen.
En wat betreft de guidance voor 2020 heeft Biocartis natuurlijk een harde les geleerd in 2019 en zal nu naar mijn verwachting eerder relatief voorzichtig zijn in hun guidance voor 2020.
Beter en veiliger is het dan om mogelijk van kwartaal op kwartaal positief te gaan verrassen in 2020.
Met het recente jaar 2019 in gedachten zou ik hen deze strategie ook geheel niet kwalijk nemen.
Ik ben ook van mening dat ze een voorzichtige guidance zullen geven, maar zelfs met een voorzichtige guidance (in hun ogen) kunnen ze nog positief verrassen (in de ogen van de markt). Japan is de sleutel. BL
brightlight schreef op 17 januari 2020 21:35 :
[...]
Ik ben ook van mening dat ze een voorzichtige guidance zullen geven, maar zelfs met een voorzichtige guidance (in hun ogen) kunnen ze nog positief verrassen (in de ogen van de markt). Japan is de sleutel.
BL
Ik begrijp wat je zegt maar kijk zelf vooral uit naar Donderdag 23 April met de eerste harde feiten van 2020 middels de 1e kwartaalcijfers 2020.
BL We definitely are not in agreement on this issue. I think Idylla is currently finding its market niche in a landscape where NGS is dominating work flow and the press clippings. That is part of the reason the Journal of Clinical Pathology is flow charting ways in which Idylla may be incorporated into the work flow in a manner that compliments the strength of NGS methods. jcp.bmj.com/content/71/9/757 That said, bells and whistles like whole genome mapping are sexy, but when it comes right down to it I think the market will focus on fast, low cost answers to questions like will this woman with breast cancer benefit from chemotherapy or not? As long as BCART focuses on assays with actionable results I think there is a very lucrative place for them in the market. Have a great weekend. FL
Here is the quote I was referring to. I'll start using the boards quote feature "There are quite a few posts about NGS lately. I think we should frame this, for those investors who don't want to dig this deep into the technical side, that we are talking about something that might (or might not) become a problem for Bcart in five years time or later. By that time Bcart will have evolved too, and rest assured that Bcart is monitoring NGS and other cutting edge technologies closely." BL BL We definitely are not in agreement on this issue. I think Idylla is currently finding its market niche in a landscape where NGS is dominating work flow and the press clippings. That is part of the reason the Journal of Clinical Pathology is flow charting ways in which Idylla may be incorporated into the work flow in a manner that compliments the strength of NGS methods. jcp.bmj.com/content/71/9/757 That said, bells and whistles like whole genome mapping are sexy, but when it comes right down to it I think the market will focus on fast, low cost answers to questions like will this woman with breast cancer benefit from chemotherapy or not? As long as BCART focuses on assays with actionable results I think there is a very lucrative place for them in the market. Have a great weekend. FL
Ik denk toch ook da in de korte termijn Japan de sleutel is zeker om het aantal idylla’s fors te kunnen opdrijven . We hebben kunnen zien in het laatste kwartaal dat als het aantal idylla’s groter word dit een significante impact kan hebben op het cartridge volume . In Amerika spelen andere krachten denk ik met een sterk gepolitiseerde FDA zal het daar van de partners afhangen denk ik hoe snel er market acceptance komt . Ik zou ook heel graag wa nieuws zien uit het Wonfo kamp da heeft toch al een pak geld gekost en als ge spreekt van ne markt China is er wel enen da zou nen enorme trigger kunnen zijn naar de beurskoers toe
ben er verleden week er ook ingestapt en denk ook wel dat we nog mooi kunnen stijgen , we komen ook van heel ver
brightlight schreef op 17 januari 2020 19:49 :
There are quite a few posts about NGS lately. I think we should frame this, for those investors who don't want to dig this deep into the technical side, that we are talking about something that might (or might not) become a problem for Bcart in five years time or later. By that time Bcart will have evolved too, and rest assured that Bcart is monitoring NGS and other cutting edge technologies closely.
BL
This article describes how the current international standard for EGFR Lung molecular pathology analysis is currently NGS methods. However, in approximately 37% of these NGS analyses invalid/unactionable results are obtained. Hetrogeneity, small sample size, etc can eaffect the NGS results. Idylla can be used to obtain actionable results in most of these cases. www.abacusdx.com/media/jclinpath-2018...
Based on the last couple posts, I believe that Idylla niche is smaller pathology labs and clinical settings and as a rescue analysis in larger labs where valid NGS results cannot be obtained. This is still a great potential market. Idylla is limited to about 4 or 5 analyses per console unit per day. Even the 8 unit models would be limited to 30 to 40 samples per day. For this reason large high throughput large labs are likely to employ Idylla as a first line mDx analysis method. Their use is likely to be limited to reducing the number of non congruent NGS results. there are a number of great marketing angles once Idylla is approved for diagnostic use. FL FL
While current diagnostic protocols for lung cancer, show a preference for NGS methods, the author proposes that Idylla be used to rescue the relatively large number of NGS failures. Here are the insights from the previously referenced publication addressing NGS use vs Idylla. Discussion This study data, besides confirming that NGS and Idylla are both accurate to detect EGFR activating mutations, show that the Idylla system is a viable option for rapid genotyping in NGS ‘invalid’ cases. Although updated international guidelines represent the scientific backbone for lung cancer biomarker testing, they do not necessarily reflect real-world routine practice, as local issues require local solutions.10 Indeed, the standard of practice in large and comprehensive cancer treatment centres is far different from that of less specialised settings. The very recent revised guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology recommend that NGS panels should be preferred over single gene tests. Indeed, beyond EGFR also the BRAF, ERBB2 (HER2), KRAS and MET mutational status may be assessed by DNA-based NGS assays. Moreover, compared with sequential single gene testing NGS may be useful to spare clinical samples, whose abundance in neoplastic component is often limited, and, in clinical terms, to help patients find appropriate clinical trials. However, while technology is advancing at a rapid pace and several DNA/RNA-based high-throughput technological solutions are emerging, currently NGS assays are often still limited to DNA alterations detection only, while most testing laboratories still strongly rely on immunohistochemical or fluorescent in situ hybridisation assays to detect ALK and ROS1 alterations. Thus, single gene testing methods are still acceptable to detect EGFR mutations provided that the recommended 10 working days’ TAT is met. In this setting, the timely communication between oncologists and molecular pathologists is crucial, in particular for acute deteriorating patient clinical management. Our data showed that, when clinical decisions should be taken quickly and when saving time is a crucial issue, since days have been spent for an ‘invalid’ NGS result, Idylla can provide a solution. As a general rule, regardless of the sample type, we directly pipetted in the cartridge from 3 up to 10 µL of extracted DNA preparation. Indeed, in this study, Idylla ‘rescued’ a large portion of cases (20/25; 80%) whose preliminary assessment by NGS was unfeasible (figure 4). Therefore, we propose an algorithm that could be used for clinical determination of EGFR mutational status Idylla, thanks to its capability of using only one FFPE slice Figure 3 Case 63. Evaluation of DNA quality and quantity relative by a microfluidic platform based on electrophoretic system (4200 TapeStation, Agilent). The electrophoretic profile features highly fragmented DNA. The poor DNA integrity number (DIN value 1.1) explained how this case failed both when processed by next generation sequencing (NGS) and by Idylla. FU, fluorecence unit. J Clin Pathol: first published as 10.1136/jclinpath-2018-205197 on 24 May 2018. Downloaded from jcp.bmj.com/ on 7 June 2018 by guest. Protected by copyright. Discussion This study data, besides confirming that NGS and Idylla are both accurate to detect EGFR activating mutations, show that the Idylla system is a viable option for rapid genotyping in NGS ‘invalid’ cases. Although updated international guidelines represent the scientific backbone for lung cancer biomarker testing, they do not necessarily reflect real-world routine practice, as local issues require local solutions.10 Indeed, the standard of practice in large and comprehensive cancer treatment centres is far different from that of less specialised settings.10 The very recent revised guidelines from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology recommend that NGS panels should be preferred over single gene tests.11 Indeed, beyond EGFR also the BRAF, ERBB2 (HER2), KRAS and MET mutational status may be assessed by DNA-based NGS assays. Moreover, compared with sequential single gene testing NGS may be useful to spare clinical samples, whose abundance in neoplastic component is often limited, and, in clinical terms, to help patients find appropriate clinical trials. However, while technology is advancing at a rapid pace and several DNA/RNA-based high-throughput technological solutions are emerging, currently NGS assays are often still limited to DNA alterations detection only, while most testing laboratories still strongly rely on immunohistochemical or fluorescent in situ hybridisation assays to detect ALK and ROS1 alterations.12 Thus, single gene testing methods are still acceptable to detect EGFR mutations provided that the recommended 10 working days’ TAT is met.11 In this setting, the timely communication between oncologists and molecular pathologists is crucial, in particular for acute deteriorating patient clinical management.5 Our data showed that, when clinical decisions should be taken quickly and when saving time is a crucial issue, since days have been spent for an ‘invalid’ NGS result, Idylla can provide a solution. As a general rule, regardless of the sample type, we directly pipetted in the cartridge from 3 up to 10 µL of extracted DNA preparation. 4 Indeed, in this study, Idylla ‘rescued’ a large portion of cases (20/25; 80%) whose preliminary assessment by NGS was unfeasible (figure 4). Therefore, we propose an algorithm that could be used for clinical determination of EGFR mutational status Idylla, thanks to its capability of using only one FFPE slice Figure 3 Case 63. Evaluation of DNA quality and quantity relative by a microfluidic platform based on electrophoretic system (4200 TapeStation, Agilent). The electrophoretic profile features highly fragmented DNA. The poor DNA integrity number (DIN value 1.1) explained how this case failed both when processed by next generation sequencing (NGS) and by Idylla. FU, fluorecence unit. J Clin Pathol: first published as 10.1136/jclinpath-2018-205197 on 24 May 2018. Downloaded from jcp.bmj.com/ on 7 June 2018 by guest. Protected by copyright.
FL, thanks for providing us with this elaborate update on the state of affairs concerning NGS and the ways in which Bcart can benefit from NGS's shortcomings. Concerning Bcart, judging from the recent price action, it seems to me the market is slowly waking up to the fact that Bcart has an enormous growth potential on offer at a very fair share-price. A rarity in these markets. BL
BL As we have discussed in the past, the current valuation metrics relative to its MDx peers certainly would justify closing the S.P. gap that developed in early September. As you have pointed out there are numerous potential catalysts that can emerge throughout the year. With regards to the market, the final piece necessary to unlock much wider access to the US and Japan is the final content registration/FDA approval. The following points suggest that these approvals will come: 1) The expansive publications positively compare Idylla results to other methods; 2) The fact that the consoles and the 1st content cartridge have already received approval; 3) The partner clout/FDA connections. 4) The urgent need for timely, quality, cost effective MDx data. The smaller hospital/clinic market would seem to be wide open since many of these facilities are only beginning to utilize MDx data for decision making. The inroads into larger pathology labs, etc will likely occur on a product by product basis, OncoTypeDx breast could quickly gain acceptance on the basis of the TailorX study. Although it is unclear how long the assay will be run in a lab in the U.S. The lung cancer guidance from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology favors NGS. However, even in this market a huge niche exists since more than a third of the NGS assays provide inconclusive results. In 80% of these cases Idylla has been able to take the original sample used in the NGS assay and recover actionable results. You can bet the sales team will emphasize these studies as soon as possible. My point is that the sales pitch will need to be directed to each practice. The addressable market seems to be huge since relative to the competing technologies, Idylla is much more cost effective. FL
nat1966 schreef op 18 januari 2020 18:59 :
ben er verleden week er ook ingestapt en denk ook wel dat we nog mooi kunnen stijgen , we komen ook van heel ver
Groot gelijk. En de kunst is, om op deze trein (lang genoeg) te blijven zitten.
Nieuwe US studie: NCT04232020 - A Retrospective Validations Microsatellite Instability (MSI) Testing v Mismatch Repair (MMR) in Gastric Adenocarcinoma - clinicaltrials.gov/ct2/show/study/NCT...
Probleem is dat ik graag reis met de trein, dus met eraf springen zal ik het nie gemakkelijk hebben.
Tronald Thanks for the link to the trial posting. Do you know whether the test location is limited to just the Royal Cornwall Hospital? FL
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee